HUE054347T2 - MK2 inhibitorok és azok alkalmazásai - Google Patents

MK2 inhibitorok és azok alkalmazásai

Info

Publication number
HUE054347T2
HUE054347T2 HUE15842903A HUE15842903A HUE054347T2 HU E054347 T2 HUE054347 T2 HU E054347T2 HU E15842903 A HUE15842903 A HU E15842903A HU E15842903 A HUE15842903 A HU E15842903A HU E054347 T2 HUE054347 T2 HU E054347T2
Authority
HU
Hungary
Prior art keywords
inhibitors
Prior art date
Application number
HUE15842903A
Other languages
English (en)
Inventor
Matthew David Alexander
Claudio Chuaqui
John Malona
Joseph John Mcdonald
Yike Ni
Deqiang Niu
Russell C Petter
Juswinder Singh
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of HUE054347T2 publication Critical patent/HUE054347T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
HUE15842903A 2014-09-17 2015-09-16 MK2 inhibitorok és azok alkalmazásai HUE054347T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
HUE054347T2 true HUE054347T2 (hu) 2021-08-30

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15842903A HUE054347T2 (hu) 2014-09-17 2015-09-16 MK2 inhibitorok és azok alkalmazásai

Country Status (30)

Country Link
US (5) US9458175B2 (hu)
EP (2) EP3912981A1 (hu)
JP (3) JP6556225B2 (hu)
KR (1) KR102457848B1 (hu)
CN (1) CN106998692B (hu)
AU (1) AU2015317741B2 (hu)
BR (1) BR112017005266B1 (hu)
CA (1) CA2961607C (hu)
CL (1) CL2017000576A1 (hu)
CO (1) CO2017003279A2 (hu)
CY (1) CY1124215T1 (hu)
DK (1) DK3193611T3 (hu)
EA (1) EA037299B1 (hu)
EC (1) ECSP17023281A (hu)
ES (1) ES2874561T3 (hu)
HR (1) HRP20210529T1 (hu)
HU (1) HUE054347T2 (hu)
IL (1) IL251051B (hu)
LT (1) LT3193611T (hu)
MA (1) MA40534B1 (hu)
MX (2) MX2017003359A (hu)
NZ (1) NZ730603A (hu)
PL (1) PL3193611T3 (hu)
PT (1) PT3193611T (hu)
RS (1) RS62017B1 (hu)
SA (1) SA517381115B1 (hu)
SG (2) SG10201902326XA (hu)
SI (1) SI3193611T1 (hu)
TW (1) TWI744217B (hu)
WO (1) WO2016044463A2 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
EP3912981A1 (en) 2014-09-17 2021-11-24 Celgene Car Llc Mk2 inhibitors and uses thereof
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
CN110678471B (zh) * 2017-03-16 2022-09-13 西建卡尔有限责任公司 Mk2抑制剂及其合成和中间体
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
AU2018236286B2 (en) * 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
EP3969456A4 (en) * 2019-05-17 2023-01-25 Celgene CAR LLC METHODS OF TREATMENT OF MK2-MEDIATED DISEASE
US20230130766A1 (en) * 2020-02-14 2023-04-27 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
EP4185382A1 (en) * 2020-07-24 2023-05-31 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
TW202328141A (zh) * 2021-08-27 2023-07-16 大陸商瑞石生物醫藥有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
PE20090480A1 (es) 2007-07-16 2009-05-24 Novartis Ag Derivados de lactama tetraciclicos
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
US10934487B2 (en) 2012-02-22 2021-03-02 Merck Patent Gmbh Liquid crystalline medium
JPWO2013146963A1 (ja) * 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2014045268A1 (en) * 2012-09-24 2014-03-27 Speede Claremont Mobile sender controlled data access and data deletion method and system
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2908098A1 (en) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
EP3912981A1 (en) 2014-09-17 2021-11-24 Celgene Car Llc Mk2 inhibitors and uses thereof
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
CN110678471B (zh) 2017-03-16 2022-09-13 西建卡尔有限责任公司 Mk2抑制剂及其合成和中间体
EP3969456A4 (en) 2019-05-17 2023-01-25 Celgene CAR LLC METHODS OF TREATMENT OF MK2-MEDIATED DISEASE
EP4185382A1 (en) 2020-07-24 2023-05-31 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
CN106998692A (zh) 2017-08-01
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US20210053984A1 (en) 2021-02-25
EP3193611B1 (en) 2021-03-24
LT3193611T (lt) 2021-08-25
AU2015317741B2 (en) 2020-01-16
MX2017003359A (es) 2017-11-22
EA037299B1 (ru) 2021-03-05
JP6556225B2 (ja) 2019-08-07
CL2017000576A1 (es) 2017-12-01
US10253040B1 (en) 2019-04-09
JP2019194236A (ja) 2019-11-07
SA517381115B1 (ar) 2021-03-09
WO2016044463A3 (en) 2016-09-01
EA201790380A1 (ru) 2017-08-31
PL3193611T3 (pl) 2021-10-04
DK3193611T3 (da) 2021-05-10
MX2020005213A (es) 2020-08-20
MA40534A (fr) 2016-03-24
AU2015317741A1 (en) 2017-04-20
BR112017005266B1 (pt) 2022-11-01
US20190375762A1 (en) 2019-12-12
US9790235B2 (en) 2017-10-17
US9458175B2 (en) 2016-10-04
CA2961607A1 (en) 2016-03-24
JP7375072B2 (ja) 2023-11-07
IL251051A0 (en) 2017-04-30
JP2017529367A (ja) 2017-10-05
CA2961607C (en) 2023-03-28
CY1124215T1 (el) 2022-05-27
ECSP17023281A (es) 2017-06-30
US11584757B2 (en) 2023-02-21
JP2022078315A (ja) 2022-05-24
EP3193611A2 (en) 2017-07-26
SG11201701861RA (en) 2017-04-27
KR102457848B1 (ko) 2022-10-25
US10577380B2 (en) 2020-03-03
TWI744217B (zh) 2021-11-01
WO2016044463A2 (en) 2016-03-24
PT3193611T (pt) 2021-05-28
IL251051B (en) 2019-11-28
EP3912981A1 (en) 2021-11-24
NZ730603A (en) 2024-02-23
EP3193611A4 (en) 2018-02-28
BR112017005266A2 (pt) 2017-12-12
CO2017003279A2 (es) 2017-09-29
US20160075720A1 (en) 2016-03-17
TW201617351A (zh) 2016-05-16
SI3193611T1 (sl) 2021-08-31
US20170114073A1 (en) 2017-04-27
SG10201902326XA (en) 2019-04-29
CN106998692B (zh) 2020-09-08
RS62017B1 (sr) 2021-07-30
KR20170063734A (ko) 2017-06-08
MA40534B1 (fr) 2021-04-30

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251051A0 (en) mk2 inhibitors and their uses
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
GB201411197D0 (en) Composition and use thereof
GB201605126D0 (en) Inhibitors and their uses
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
HUE052359T2 (hu) Hidrofluorolefin-bázisú készítmény és alkalmazása
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
IL251077B (en) Integrin inhibitors and their use
HK1250926A1 (zh) 抑制劑及其應用
IL251078A0 (en) Integrin inhibitors and their use
GB201411196D0 (en) Composition and use thereof
GB201408091D0 (en) Methods and uses
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses
GB201418154D0 (en) Inhibitors
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses